Kodiak Sciences Inc. Announces Follow-Up Data for KSI-101 from the Apex Study
Kodiak Sciences announced today positive follow-up data from its Phase 1b APEX study of KSI-101, showing ≥90% of MESI patients achieved absence of retinal fluid at week 20, supporting advancement to Phase 3 trials.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.